Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 15,450
+1,180 (8.27%)
Last updated: Aug 14, 2025
Envestnet Revenue
Prestige BioPharma had revenue of 3.34B KRW in the quarter ending March 31, 2025, with 422.99% growth. This brings the company's revenue in the last twelve months to 8.66B, up 776.76% year-over-year. In the fiscal year ending June 30, 2024, Prestige BioPharma had annual revenue of 689.08M with 325.77% growth.
Revenue (ttm)
8.66B
Revenue Growth
+776.76%
P/S Ratio
21.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
188.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |
| LigaChem Biosciences | 146.42B |